Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2022-02, Vol.36 (2), p.580-582
Hauptverfasser:	Damaschin, Carla, Goergen, Helen, Kreissl, Stefanie, Plütschow, Annette, Breywisch, Frank, Mathas, Stephan, Meissner, Julia, Sökler, Martin, Topp, Max S., Vucinic, Vladan, Zimmermann, Andreas, von Tresckow, Bastian, Fuchs, Michael, Engert, Andreas, Borchmann, Peter, Eichenauer, Dennis A.
Format:	Artikel
Sprache:	eng
Schlagworte:	692/308/2779/109/1941 692/699/1541/1990/291 692/700/565/1436/1437 Adolescent Adult Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bleomycin - administration & dosage Brentuximab Vedotin - administration & dosage Cancer Research Chemotherapy Clinical Trials, Phase II as Topic - statistics & numerical data Critical Care Medicine Cyclophosphamide - administration & dosage Drug dosages Etoposide - administration & dosage Female Fertility Follow-Up Studies Hematology Hodgkin Disease - drug therapy Hodgkin Disease - pathology Hodgkin's lymphoma Hospitals Humans Immunotherapy Infertility Intensive Internal Medicine Letter Leukemia Lymphoma Male Medicine Medicine & Public Health Middle Aged Monoclonal antibodies Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - pathology Neoplasms, Second Primary - drug therapy Neoplasms, Second Primary - pathology Oncology Prognosis Randomized Controlled Trials as Topic - statistics & numerical data Stem cell transplantation Survival Rate Targeted cancer therapy Tumors Vincristine - administration & dosage Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:
ISSN:	0887-6924 1476-5551
DOI:	10.1038/s41375-021-01386-z